Novi, United States
Delphinus Medical Technologies, Inc. is pioneering advancements in the field of medical imaging, particularly in the early detection of breast cancer. Founded in 2010 and headquartered in United States, this innovative company emerged as a spin-out of the Karmanos Cancer Institute in Detroit, MI.
Specializing in the Biotechnology, Health Care, and Medical Devices industries, Delphinus is on the forefront of ultrasound technology with its product, SoftVue™. This device, enhanced by proprietary TriAD™ technology, offers a unique imaging technique utilizing a ring transducer—a first in its field. Its ability to capture reflection echoes from all directions sets it apart, despite not being a replacement for screening mammography. The device has already earned 510(k) clearance from the U.S. FDA.
The company is committed to a mission as expressed in its slogan: "Delivering medical innovations to transform early detection of breast cancer and save women’s lives all over the world." Recently, Delphinus secured a $12.00M Venture Round investment on August 22, 2023, led by Trinity Capital, reinforcing investor confidence in its growth trajectory and technological potential.
